# # # #
This week an announcement was made regarding The Edmond J. Safra Accelerating Clinical Treatments for Parkinson’s Disease (EJS-ACT PD) Initiative.
It is hoping to revolutionise the way clinical trials for potentially disease-modifying drugs for Parkinson’s are conducted.
The project is focused on the setting up a multi-arm, multi-stage (MAMS) platform for evaluating new therapies for PD.
In today’s post, we will discuss what MAMS trials involve and the current details of the EJS-ACT PD initiative.
# # # #
This week I boarded a train for the first time in 16 months and made my way down to London. It felt a wee bit surreal.
I arrived at Liverpool street station and was immediately shocked by the lack of crowds, the lack of face masks (seriously?!? I’ve had my two jabs as well, but I’m still wearing my mask – you are nuts if you don’t!), and the large number of empty shops. How the world has changed.
In the early morning light, I walked across central London towards St Pancras station – the weather was spectacular and it was an incredible pleasure to stroll through some old stomping grounds.
At St Pancras station, I made my way to the enormous Francis Crick institute, where a group of Parkinson’s researchers and advocates were gathering for a really intriguing meeting.
What was the meeting about?
Continue reading “EJS-ACT PD”
Each year King’s College London holds the Edmond J. Safra Memorial Lecture. It is a public event – exploring cutting-edge research on Parkinson’s – held in honour of the late philanthropist and financier, Mr Edmond J Safra, .
I was lucky enough to attend this year’s event (entitled A vision of tomorrow: How can technology improve diagnosis and treatment for Parkinson’s patients?). It highlighted the fantastic research being carried out by Professor Marios Politis and his team.
During the Q&A session of the event though, a question was asked from the audience regarding what the evolutionary advantage of Parkinson’s might be. The question drew a polite chuckle from the audience.
But the question wasn’t actually as silly as some might think.
In today’s post we look at some evidence suggesting an evolutionary advantage involving Parkinson’s.
King’s College London Chapel. Source: Schoolapply
Despite the impressive name, King’s College London is not one of the grand old universities of England.
Named after its patron King George IV (1762-1830), the university was only founded in 1829 (compare this with 1096 for Oxford and 1209 for Cambridge; even silly little universities like Harvard date back further – 1636). The university is spread over five separate campuses, geographically spread across London. But if you ever get the chance to visit the main Strand campus, ask for the chapel and take a moment to have a look – it is very impressive (the image above really doesn’t do it justice).
As I mentioned in the intro, each year King’s College London holds the Edmond J. Safra Memorial Lecture. It is an event that is open to the public and it involves a discussion regarding innovative new research on Parkinson’s. The evening is held in honour of the late Mr Edmond J Safra.
Edmond J. Safra. Source: Edmondjsafrafoundation
This year, Professor Marios Politis and members of his research group were presenting lectures on “How can technology improve diagnosis and treatment for Parkinson’s”. The lectures were very interesting, but the reason I am writing about it here is because during the question and answer session at the end of the lectures, the following question was asked:
“What’s the evolutionary advantage of Parkinson’s?”
Given the debilitating features of the condition, the audience was naturally amused by the question. And there was most likely several people present who would have thought the idea of any evolutionary advantage to Parkinson’s a ridiculous concept.
But it’s not.
And there is actually research to suggest that something evolutionary could be happening with Parkinson’s.
?!?!? What do you mean?
Continue reading ““What’s the evolutionary advantage of Parkinson’s?””